Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 25;12(21):2518.
doi: 10.3390/cells12212518.

Exhaled Nitric Oxide as Biomarker of Type 2 Diseases

Affiliations
Review

Exhaled Nitric Oxide as Biomarker of Type 2 Diseases

Mauro Maniscalco et al. Cells. .

Abstract

Nitric oxide (NO) is a short-lived gas molecule which has been studied for its role as a signaling molecule in the vasculature and later, in a broader view, as a cellular messenger in many other biological processes such as immunity and inflammation, cell survival, apoptosis, and aging. Fractional exhaled nitric oxide (FeNO) is a convenient, easy-to-obtain, and non-invasive method for assessing active, mainly Th2-driven, airway inflammation, which is sensitive to treatment with standard anti-inflammatory therapy. Consequently, FeNO serves as a valued tool to aid the diagnosis and monitoring of several asthma phenotypes. More recently, FeNO has been evaluated in several other respiratory and/or immunological conditions, including allergic rhinitis, chronic rhinosinusitis with/without nasal polyps, atopic dermatitis, eosinophilic esophagitis, and food allergy. In this review, we aim to provide an extensive overview of the current state of knowledge about FeNO as a biomarker in type 2 inflammation, outlining past and recent data on the application of its measurement in patients affected by a broad variety of atopic/allergic disorders.

Keywords: COPD; allergy; asthma; biomarkers; mediators; outcome.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic representation of the Th2 pathway. Dendritic cell activation by damaged epithelial cells secreting interleukin (IL)-4 prompts Th0 cells to differentiate into Th2 cells. Th2 cells secrete IL-5, among other cytokines, which represents the main stimulus for the production and recruitment of eosinophils (orange arrow) at the level of the target organ. Infections or exposure to pollutants induce epithelial cells to release the so-called alarmins (IL-25, IL-33, thymic stromal lymphopoietin (TSLP)) which activate innate lymphoid cells 2 (ILC2), which produce Th2 cytokines. IL-13, mainly secreted by eosinophils, activates the expression (orange arrow) of inducible nitric oxide synthase (iNOS) and increases the production of NO. AR, allergic rhinitis; CRS, chronic rhinosinusitis; EoE, eosinophilic esophagitis; AD, atopic dermatitis.

References

    1. Kiss H., Orlos Z., Gellert A., Megyesfalvi Z., Mikaczo A., Sarkozi A., Vasko A., Miklos Z., Horvath I. Exhaled Biomarkers for Point-of-Care Diagnosis: Recent Advances and New Challenges in Breathomics. Micromachines. 2023;14:391. doi: 10.3390/mi14020391. - DOI - PMC - PubMed
    1. Moncada S., Palmer R.M., Higgs E.A. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 1991;43:109–142. - PubMed
    1. Escamilla-Gil J.M., Fernandez-Nieto M., Acevedo N. Understanding the Cellular Sources of the Fractional Exhaled Nitric Oxide (FeNO) and Its Role as a Biomarker of Type 2 Inflammation in Asthma. Biomed. Res. Int. 2022;2022:5753524. doi: 10.1155/2022/5753524. - DOI - PMC - PubMed
    1. American Thoracic Society. European Respiratory Society ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am. J. Respir. Crit. Care Med. 2005;171:912–930. doi: 10.1164/rccm.200406-710ST. - DOI - PubMed
    1. Medrek S.K., Parulekar A.D., Hanania N.A. Predictive Biomarkers for Asthma Therapy. Curr. Allergy Asthma Rep. 2017;17:69. doi: 10.1007/s11882-017-0739-5. - DOI - PubMed

Publication types